The monoclonal antibody 19-9 was originally raised against a human colon carcinoma cell line, SW 116 (Koprowski et al., 1981) . The antigen defined is a carbohydrate determinant of a circulating antigen designated CA19-9 . A radioimmunoassay to detect CA19-9 in serum was recently developed and elevated levels of CA19-9 have been found association with a wide range of benign and malignant conditions (Del Villano & Zurawski, 1983) including ovarian carcinomas (Ricolleau et al., 1983) .
To date CA125 has shown the most clinical promise as a marker for ovarian tumours Canney et al., 1984) . The present study has investigated CA19-9 levels in the serum of patients with known ovarian carcinoma in whom CA125 levels were also recently measured. The object was to test CA19-9 as a serum marker alone and in comparison with CA125 to see if the pair of antigens provided more information than each one separately.
Sera of 55 patients with histologically proven ovarian adenocarcinoma, known to have persisted after laparotomy, or to have recurred after previous treatment, were examined for CA19-9 levels.
The sampling procedure, treatment methods and assessment of patients were as described in the first part of the study (Canney et al., 1984) . CA19-9 was measured using a solid phase sandwich radioimmunoassay (International CIS, UK, Ltd., London). Sera were stored at -20°C until assayed. The upper limit of normal was taken as 33uml-1, a level exceeded by 1% of 260 presumed normal subjects (manufacturers information).
CA125 was also measured using a commercially available immunoradiometric assay (International CIS, UK Ltd) as previously described (Canney et al., 1984 Table I . The overall sensitivity was 29% with a proportion of all the histological types being positive. A further two patients with granulosa cell tumours had CAI 9-9 levels < 33 U ml-1. There was no correlation between elevation of serum CA 19-9 and bulk of residual tumour, the antigen having been detected as frequently in patients with minimal residual disease (no lesion >2 cm) as in patients with gross bulk disease (any lesion > 10 cm). (Table II) .
Twelve patients whose initial CA19-9 level was elevated had serial levels performed during the course of their treatment. Changes in measured serum antigen level versus clinical response are shown in Figure 1 . No patient who responded to treatment had a rising CAl9-9 titre, and in all three cases the antigen level was within the normal range at the conclusion of treatment. This is in marked contrast to those patients with static or progressive disease, none of whom showed a similar fall in CA19-9 serum level. Overall 40 patients were available for assessment of response to chemotherapy of whom 23 (58%) responded. The number of responses by result of the marker assays is shown in Table III . The proportion of responders (23%) in the CA19-9+ group was significantly lower than in the CA19-9-group (74%) (x2=9.34; P<0.01). Comparison of the sensitivities of is shown in Table IV. The overall sensitivity for CA125 was 76% in this group of patients, whilst the combined sensitivity, either CA125 or CAl9-9 positive, rose to 80%.
For monitoring the course of the disease, variations in CA19-9 levels corresponded to those in CA125 levels in 8 cases, and reflected the clinical situation accurately. In three cases the serial changes in CA19-9 levels provided a better (Figure 2 ). In one case an initial normal CA19-9 level rose during disease progression, whilst CA125 remained negative throughout. When examined immunohistochemically CA19-9 has been shown to occur in association with ovarian adenocarcinomas (Charpin et al., 1982 ) the mucinous histological types reacting much more frequently than serous types. CA19-9 has been shown to be secreted into the serum in ovarian cancer patients (Ricolleau et al., 1983) but results of serum assays have not previously been reported in detail. The sensitivity of the CA19-9 assay, 29%, is not adequate for it to be used alone as a marker for ovarian tumours. However, a raised CA19-9 level before chemotherapy does appear to be a significant adverse prognostic factor. This was not related to the presence of bulk disease, as the percentage of patients with elevated CA19-9 levels was independent of the bulk of disease. No such prognostic significance was apparent for the CA125 antigen in the series. When the CA19-9 level was elevated there was a good correlation with the clinical course of the disease, in those patients in whom serial levels were measured. In three instances this was more evident than the serial changes in CA125 level, which fell initially before rising again as the disease progressed.
CA125 is the ovarian antigen which has shown the most clinical promise to date Canney et al., 1984) . However, it seems likely that no tumour associated antigen per se will give useful information in all patients, not least because expression is frequently heterogeneous in a given neoplasm, regardless of the histological appearance of the cells (Kabawat et al., 1983) . However, the concept of using more than one marker is well established in the deployment of HCG and AFP to monitor testicular tumours. The use of a second marker, could theoretically increase serological detectability, if the substance were secreted by additional subpopulations of neoplastic cells. The efficacy of monitoring response to therapy would thereby be increased. The "worst case" serial marker results most accurately reflect the eventual response in the case of HCG and AFP, and a similar situation was evident in 4 patients in our series. Differential secretory activity of cells expressing CA125 and CA19-9 could explain, at least in part, the varied changes in serial levels observed in response to chemotherapy and this interpretation could be amenable to evaluation by immunohistochemistry. The present data are consistent with the view that CA19-9 secretion is predominantly a property of the more malignant, or drug resistant, cells within the carcinomas studied in this series.
The specificity (false positive rate) will be worsened by using a pair of markers but this is not relevant once a histological diagnosis has been made.
Apart from its prognostic significance, measurement of CA19-9 gave additional information to CA125 in 6 cases (11%), including the two patients who were CA19-9+ but CA125-, although the sensitivity of CA125, at 76%, was slightly lower in this particular group of 55 patients than in previously reported series Canney et al., 1984) and in all patients who have had CA125 levels measured at this institute where the overall sensitivity is currently 81/97 (83%). However, at present no other antigenic marker is as readily available as an alternative or addition to CA125 and an initial CA 19-9 assay could be of some clinical value.
